Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Novo Holdings

Industrifonden

Boehringer Ingelheim Venture Fund

LU Holding

Asgard Therapeutics

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Euro

Apple Mobile Web Clips Icon

Google Font API

Content Delivery Network

Google Maps

WordPress

Senior Scientist Gene Therapy

Emilie Renaud

Senior Scientist

Michele Tavecchio

Aleksei Zeifman

Jonas Jendi

Søren Møller

Philipp Müller

Joao Ribas

Fábio Rosa

Co-founder and Head of Research

Filipe Pereira

Co-founder, Board Member and Head of Innovation

Lars Hedbys

Chairman Of The Board

Cristiana Pires

Co-Founder and CEO

Europe Companies With Less Than $500M in Revenue (Top 10K)

Europe, Middle East, and Africa (EMEA) Early Stage Companies With More Than $1M in Revenue

Therapeutics Companies With Less Than $10M in Revenue (Top 10K)

Industrifonden Portfolio Companies

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.

Johnson & Johnson Innovation – JJDC

RV Invest

Series A - Asgard Therapeutics

Seed Round - Asgard Therapeutics

Venture Round - Asgard Therapeutics

Lund

Skane Lan

Sweden

Europe

Asgard's 'direct reprogramming strategy' garners €30M series A

Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer

Asgard Therapeutics Raises €30M in Series A Financing

Asgard Therapeutics on LinkedIn: #asgard #pipeline #cancer #immunotherapy #lifesciences #biotech #oncology | 73 ...

Asgard Therapeutics on LinkedIn: #lifesciences #biotech #cancer #immunotherapy #oncology | 32 comments

United States

North America

Belarus

Mexico

Tanzania

Africa

Biotechnology company focused on developing drugs that target the peripheral nervous system to treat cancer and other diseases.

Cygnal Therapeutics

Biotech company specializing in developing plant-based therapeutics for various diseases, including cancer.

Neoplants

Company dedicated to the development of novel immunotherapies for cancer treatment, particularly focusing on cell reprogramming techniques.

Xios Therapeutics

Asgard Therapeutics is a Swedish private biotech company that explores direct cell reprogramming technologies to develop cancer immunotherapies. The company's lead program, AT-108, is designed to initiate immune responses mediated by professional antigen presenting cells, overcoming logistical and manufacturing hurdles of conventional cell-based therapies.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 1:06 AM	f746a9e5
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 1:06 AM	3cd49cff
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	9cbff5d8
crunchbase profile	general	Dec 4, 2024 12:45 PM	5dc66723
li profile	general	Mar 4, 2024 1:06 AM	f19657b5
translate crunchbase fundingrounds	general	Dec 4, 2024 1:39 PM	55051735
peers	general
news basic	general	Mar 4, 2024 1:06 AM	808674b3
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ASGARDTHX

Asgard Therapeutics